Til Menge

3.7k citations

46 papers · 1.9k indexed · h-index 26

Impact in

Pathology and Forensic Medicine top 1%
- Multiple Sclerosis Research Studies
Neurology top 2%
- Peripheral Neuropathies and Disorders
- Neuroinflammation and Neurodegeneration Mechanisms

Papers in ⓘ

Pathology and Forensic Medicine 31
- Multiple Sclerosis Research Studies 31
Rheumatology 16
- Systemic Lupus Erythematosus Research 11
- Rheumatoid Arthritis Research and Therapies 4

Co-authors: Olaf Stüve (14 shared papers)Bernd C. Kieseier (14 shared papers)Bernhard Hemmer (14 shared papers)Hans-Peter Hartung (6 shared papers)Claude P. Genain (8 shared papers)H.‐Christian von Büdingen (8 shared papers)Patrice H. Lalive (6 shared papers)Stefan Nessler (2 shared papers)
Journals: Neurology (4 papers)Expert Review of Neurotherapeutics (2 papers)Drugs (2 papers)European Journal of Immunology (2 papers)Multiple Sclerosis Journal (2 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Til Menge

42 papers receiving 1.8k citations

Peers

Countries citing papers authored by Til Menge

Since Specialization

Citations

This map shows the geographic impact of Til Menge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Til Menge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Til Menge more than expected).

Fields of papers citing papers by Til Menge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Til Menge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Til Menge. The network helps show where Til Menge may publish in the future.

Co-authors

The 25 scholars most cited alongside Til Menge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Til Menge Line = papers co-authored together Til Menge links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Acute Disseminated Encephalomyelitis Archives of Neurology ·Til Menge, Bernhard Hemmer, Stefan Nessler, Heinz Wiendl, Oliver Neuhaus, Hans-Peter Hartung, Bernd C. Kieseier, Olaf Stüve	2005	249
2	Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis Proceedings of the National Academy of Sciences ·Patrice H. Lalive, Til Menge, Cécile Delarasse, Bruno Della Gaspera, Danielle Pham-Dinh, Pablo Villoslada, H.‐Christian von Büdingen, Claude P. Genain	2006	126
3	Acute disseminated encephalomyelitis: an acute hit against the brain Current Opinion in Neurology ·Til Menge, Bernd C. Kieseier, Stefan Nessler, Bernhard Hemmer, Hans-Peter Hartung, Olaf Stüve	2007	97
4	Natalizumab and Progressive Multifocal Leukoencephalopathy Archives of Neurology ·Clemens Warnke, Til Menge, Hans‐Peter Hartung, Michael K. Racke, Petra D. Cravens, Jeffrey L. Bennett, Elliot M. Frohman, Benjamin Greenberg, Scott S. Zamvil, Ralf Gold, Bernhard Hemmer, Bernd C. Kieseier, Olaf Stüve	2010	86
5	Statins — a cure-all for the brain? Nature reviews. Neuroscience ·Til Menge, Hans-Peter Hartung, Olaf Stüve	2005	80
6	Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination European Journal of Immunology ·H.‐Christian von Büdingen, Stephen L. Hauser, Jean‐Christophe Ouallet, Naoyuki Tanuma, Til Menge, Claude P. Genain	2004	80
7	Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety Expert Review of Neurotherapeutics ·Divyanshu Dubey, Bernd C. Kieseier, Hans Hartung, Bernhard Hemmer, Clemens Warnke, Til Menge, William A. Miller-Little, Olaf Stüve	2015	73
8	Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica Archives of Neurology ·Sudhakar Reddy Kalluri, Zsolt Illés, Rakesh K. Srivastava, Bruce Cree, Til Menge, Jeffrey L. Bennett, Achim Berthele, Bernhard Hemmer	2010	72
9	Natalizumab restores aberrant miRNAexpression profile in multiple sclerosis and reveals a critical role for miR‐20b Annals of Clinical and Translational Neurology ·Jens Ingwersen, Til Menge, Britta Wingerath, Derya Kaya, Jonas Graf, Tim Prozorovski, Andreas Keller, Christina Backes, Markus Beier, Matthias Scheffler, Thomas Dehmel, Bernd C. Kieseier, Hans‐Peter Hartung, Patrick Küry, Orhan Aktaş	2014	68
10	Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children Multiple Sclerosis Journal ·P H Lalive, M. Häusler, Hélène Maurey, Yann Mikaeloff, Marc Tardieu, Heinz Wiendl, Michael Schroeter, Hartung Hp, BC Kieseier, Til Menge	2010	68
11	Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis Journal of Allergy and Clinical Immunology ·Til Menge, Patrice H. Lalive, H.‐Christian von Büdingen, Bruce Cree, Stephen L. Hauser, Claude P. Genain	2005	62
12	Requirement for safety monitoring for approved multiple sclerosis therapies: an overview Clinical & Experimental Immunology ·Paulus Rommer, Uwe K. Zettl, B. C. Kieseier, H-P Hartung, Til Menge, E. Frohman, Benjamin Greenberg, Bernhard Hemmer, Olaf Stüve	2013	57
13	Disease-Modifying Agents for Multiple Sclerosis Drugs ·Til Menge, Martin S. Weber, Bernhard Hemmer, Bernd C. Kieseier, H.‐Christian von Büdingen, Clemens Warnke, Scott S. Zamvil, Aaron Boster, Omar Khan, Hans Hartung, Olaf Stüve	2008	49
14	Induction of the proinflammatory cytokine interleukin‐18 by axonal injury Journal of Neuroscience Research ·Til Menge, Sebastian Jander, Guido Stoll	2001	49
15	Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects Current Pharmaceutical Design ·Martin S. Weber, Til Menge, Klaus Lehmann‐Horn, Helena Kronsbein, Uwe K. Zettl, Johann Sellner, Bernhard Hemmer, Olaf Stüve	2012	43
16	Normal Pressure Hydrocephalus Associated with Alzheimer's Disease Annals of Neurology ·Katharina Müller‐Schmitz, Natalia Krasavina‐Loka, Tuğba Yardımcı Gürel, Tim Lipka, Aschwin Kolman, Sabine Robbers, Til Menge, Milenko Kujovic, Rüdiger J. Seitz	2020	43
17	Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum Multiple Sclerosis Journal ·Marius Ringelstein, Jens Harmel, Felix Distelmaier, Jens Ingwersen, Til Menge, Kerstin Hellwig, B. C. Kieseier, Ertan Mayatepek, HP Hartung, Tania Kuempfel, Orhan Aktaş	2013	42
18	Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays Neurology ·Patrice H. Lalive, Til Menge, Ishita Barman, Bruce Cree, Claude P. Genain	2006	39
19	Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis Archives of Neurology ·Olaf Stüve, Verena I. Leussink, Ruth Fröhlich, Bernhard Hemmer, Hans‐Peter Hartung, Til Menge, Bernd C. Kieseier	2009	37
20	Pharmacological Treatment of Early Multiple Sclerosis Drugs ·Olaf Stüve, Jeffrey L. Bennett, Bernhard Hemmer, Heinz Wiendl, Michael K. Racke, Amit Bar‐Or, Wei Hu, Robert Zivadinov, Martin S. Weber, Scott S. Zamvil, Maria F Pacheco, Til Menge, Hans-Peter Hartung, Bernd C. Kieseier, Elliot M. Frohman	2008	37

About Til Menge

Til Menge is a scholar working on Pathology and Forensic Medicine, Rheumatology, Neurology, Immunology and Oncology, having authored 46 papers that have together received 1.9k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (31 papers), Peripheral Neuropathies and Disorders (14 papers), Systemic Lupus Erythematosus Research (11 papers), Polyomavirus and related diseases (7 papers), Immunotherapy and Immune Responses (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Rheumatoid Arthritis Research and Therapies (4 papers) and Cytokine Signaling Pathways and Interactions (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.0k citations), Neurology (714 citations), Rheumatology (331 citations), Immunology (445 citations) and Neurology (116 citations). Til Menge has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Olaf Stüve, Bernd C. Kieseier, Bernhard Hemmer, Hans-Peter Hartung, Claude P. Genain, H.‐Christian von Büdingen, Patrice H. Lalive, Stefan Nessler, Heinz Wiendl and Hans‐Peter Hartung. Their work appears in journals such as Neurology, Expert Review of Neurotherapeutics, Drugs, European Journal of Immunology and Multiple Sclerosis Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact